Kwembulwa Ukwelashwa Kwe-TIL: Ukuhlola Isimo Se-Cancer Immunotherapy

Ukwelashwa kwe-TIL kuhilela ukukhipha ama-lymphocyte angena ngesimila (ama-TIL), angamaseli omzimba aqinile kakhulu alwa nesimila emzimbeni wesiguli, esimila bese ewatshala ngobuningi elabhorethri. Lawa ma-TIL asebenzayo abe esefakwa emzimbeni wesiguli ukuze kuqiniswe ikhono lesimiso somzimba sokuzivikela ekuhlaseleni nasekubulaleni amangqamuzana omdlavuza. Ama-TIL asebenza ngokubona izimpawu ezithile kumaseli omdlavuza nokuqalisa impendulo yomzimba ngokumelene nawo, ekugcineni okuholela ekubhujisweni kwesimila.

Ngokusekelwe emiphumeleni yethu yokwelashwa kwezokwelapha, ukusebenza kahle kwe-TILs monotherapy kufinyelela ku-40%, okwenza kube yindlela yokwelapha isimila ephumelela kakhulu ngaphandle kokuhlinzwa okutholakalayo njengamanje. I-Bioocus ihlela uhlelo lokwelapha oluphelele lwesiguli ngasinye. Ukwelashwa okukodwa noma okuningana kuzohlanganiswa nokwelashwa kwe-Tils, okuzokhulisa izinga eliphelele elisebenzayo libe ngaphezu kuka-80%. Ukwelashwa okuhlanganisiwe kuhlose ukunciphisa umthwalo wesimila esikhathini esifushane, kanti i-tils inikeza ithuba lesiguli lokuthola ukwelashwa esikhathini eside.

Ukucaciswa okuphezulu: Amaseli e-T athile esimila azwela ama-antigen esimila, aqashelwa ama-TCR amaningi

Ukuqina kwe-tropism okunamandla: ukubonakaliswa okuphezulu kwama-receptor e-chemokine, i-tropism enamandla ye-tumor, kanye nesenzo esisheshayo

Ukubulala izimila: Ama-TIL ayasebenza futhi akhuliswe abe yi-109-1011, futhi amaseli omdlavuza asele ayasuswa ngemva kokuhlinzwa.

Umphumela oqhubekayo: Isilinganiso samaseli e-T enkumbulo siphezulu, futhi angaphila emzimbeni isikhathi eside futhi aqashwe njalo.

Ukuphepha okuphezulu: ukukhishwa, ukwandiswa, ukusabela okungenakwaliwa, kanye ne-SAE yamaseli e-TIL ezigulini ngokwazo

Ukwelashwa nge-Tils kusebenze kahle ku- I-NSCLC (umdlavuza wamaphaphu ongewona amangqamuzana amancane),I-Melanoma, Umdlavuza Webele, Umdlavuza Wesibeletho, kanye nomdlavuza wesibeletho. 

Ngaphandle kokukhishwa kwesimila esiyinhloko ngokuhlinzwa, izicubu zesimila esingaphezulu, ama-lymph node, i-pleural effusion, ama-ascites, njll., nazo zingazanywa ukukhishwa. Ukulinganiswa kokusebenza kahle kungokulandelayo: isilonda esiyinhloko ≥ isilonda esisakazekile ≥ ama-lymph node ≥ ama-ascites.

Inqubo yethu yokutshala ama-TIL athuthukiswe ngokuzimela ifinyelela izinga lempumelelo elingu-≥85%. Ngesampula evamile yezicubu engu-≥1cm3, izigidigidi zama-TIL zingatshalwa, futhi amaseli abonisa umsebenzi onamandla we-cytotoxic.

1. Ama-TIL angamaseli esiguli uqobo, ngakho-ke akukho bungozi bokwenqatshwa, okuqinisekisa ukuphepha okuphezulu.

2. Ukusabela okubi: Umkhuhlane uvamile (ngenxa yokukhishwa kwama-cytokine ngesikhathi sokuphuma kwesimila esibangelwa yi-TILs cell tumor, okubangela umkhuhlane wesikhashana, ngokuvamile ongadingi ukwelashwa okuqondile futhi oxazululeka ngokwawo).

3. Eminye imiphumela emibi ebikwe ezifundweni ihlanganisa i-thrombocytopenia, i-febrile neutropenia, umfutho wegazi ophakeme, njll., okubangelwa kakhulu yi-TILs ehlanganiswe neminye imithi efana ne-chemotherapy yangaphambi kokwelashwa (cyclophosphamide + fluorouracil), i-IL-2 enesikali esiphezulu, ama-antibodies e-PD-1 monoclonal, njll.